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Abstract
Introduction: The previous meta-analysis on the use of endothelin-receptor antagonists (ETRAs) to treat
aneurysmal subarachnoid hemorrhage (SAH) has become outdated due to recently published phase 3 clinical trials.
An up-to-date meta-analysis is needed to provide the best available evidence for the efficacy of ETRAs for
aneurysmal SAH.
Methods: We performed a systematic review and meta-analysis of published randomized controlled trials that
investigate efficacy of ETRAs in patients with aneurysmal SAH. Mortality, unfavorable outcome, delayed ischemic
neurological deficit (DIND), delayed cerebral infarction (DCI), angiographic vasospasm and adverse events were
analyzed. Meta-analysis was performed in terms of the risk ratio (RR) and 95% confidence interval (CI).
Results: Five eligible studies were reviewed and analyzed, involving 2,595 patients. The pooled RRs of mortality
and unfavorable outcome after SAH were 1.03 (95% CI = 0.77 to 1.36) and 1.07 (95% CI = 0.93 to 1.22),
respectively. The pooled RRs were 0.87 (95% CI = 0.74 to 1.03) for DCI, 0.77 (95% CI = 0.66 to 0.90) for DIND, and
0.66 (95% CI = 0.57 to 0.77) for angiographic vasospasm. There were significant increases in lung complications
(RR = 1.80, 95% CI = 1.55 to 2.09), hypotension (RR = 2.42, 95% CI = 1.78 to 3.29) and anemia (RR = 1.47, 95% CI =
1.19 to 1.83) in patients administered ETRAs.
Conclusion: There is no evidence that ETRAs could benefit clinical outcome in patients with SAH. Owing to the
increased adverse events, further clinical trials of ETRAs in SAH patients should be more carefully formulated and
designed. The present results also suggest that DCI may be a better outcome measure than vasospasm and DIND
in SAH clinical trials and observational studies.
Introduction
Spontaneous subarachnoid hemorrhage (SAH) is the
extravasation of blood into the subarachnoid spaces
filled with cerebrospinal fluid [1]. SAH accounts for 2 to
5% of all new strokes, with an overall incidence of about
9 per 100,000 person-years [2]. The outcome of patients
after SAH is generally poor: about one-half of patients
died after SAH and many survivors have long-term cog-
nitive and neurological impairment [3-5]. Vasospasm is
one of the most serious complications after SAH, found
in up to 70% of patients with SAH on angiography
Vasospasm-associated clinical manifestation, delayed
ischemic neurological deficit (DIND) and delayed cere-
bral infarction (DCI) are the leading causes of mortality
and morbidity after SAH and are widely considered
potential therapeutic targets [6,7]. Clinical trials testing
medical treatments for prevention of vasospasm have
been disappointing, with only hemodynamic therapy and
calcium antagonists having a beneficial effect, but the
efficacy of these treatments is suboptimal [8-11].
Recently, there has been increasing interest in the use
of endothelin-receptor antagonists (ETRAs) to prevent
endothelin-mediated cerebral vasospasm after aneurys-
mal SAH. Endothelin is one of the most potent endo-
genous vasoconstrictors, which is responsible for the
clinical manifestation of cerebral vasospasm following
SAH [12]. Both experimental and clinical data demon-
strate increased cerebrospinal fluid and plasma levels of
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endothelin expression in the presence of vasospasm.
There is also an increase of endothelin-receptor expres-
sion in cerebral arteries following SAH [13,14]. Previous
clinical trials and meta-analysis indicated that ETRAs can
prevent both radiographic vasospasm and DINDs, but
did not demonstrate that they can improve clinical out-
comes [15]. Owing to recently published phase 3 clinical
trials, the previous meta-analysis on the use of ETRAs to
treat aneurysmal SAH has become outdated [16]. To pro-
vide the best available evidence for the effect and safety
of ETRAs for aneurysmal SAH, we conducted an up-to-
date meta-analysis in the present article.
Materials and methods
The present study was performed according to the
PRISMA guidelines (Additional File 1). The review pro-
tocol has not been registered previously.
Type of studies included
We included only published randomized controlled
trials (RCTs) comparing ETRAs with no ETRAs or with
placebo administration for patients with acute aneurys-
mal SAH.
Types of outcome measures
The following outcomes were evaluated: mortality at the
end of scheduled follow-up; unfavorable outcome (either
death or dependency) at the end of scheduled follow-up
(dependency assessed at least 1 month after SAH); DCI
and DIND; angiographic vasospasm; and adverse events.
We defined dependency as being dependent on others
for activities of daily living; for example, having Glasgow
Outcome Scale score <4, Extended Glasgow Outcome
Scale ≤4, modified Rankin Scale score graded 3 to 5, or
Barthel Index 0 to 60 [17,18]. Angiographic vasospasm
was defined as moderate (34 to 66%) or severe (67 to
100%) arterial narrowing on digital subtraction angiogra-
phy determined by neuroradiologists [19]. DIND was
defined by a delayed decrease of consciousness by at
least two Glasgow Coma Scale levels and/or an increase
≥2 points on the abbreviated National Institutes of
Health Stroke Scale and/or a new focal neurological def-
icit [16]. DCI was defined as confirmed new hypodensi-
ties on the computed tomography (CT) scan that were
only attributable to cerebral vasospasm and delayed cer-
ebral ischemia [20].
Search strategy
We performed a systematical search of the Cochrane
Central Register of Controlled Trials, PubMed, MEDLINE,
EMBASE and Science Citation Index Expanded (SCI-
EXPANDED) from 1980 to July 2012. The details of full
electronic search strategies are presented in Additional
File 2. The reference lists of all relevant papers and
literature reviews were checked. In addition, we contacted
researchers and study authors for further information
where possible.
Study selection and data extraction
Three review authors (JM, HL and SH) independently
screened the titles, abstracts and keywords of citations
obtained from the searches of the electronic databases and
excluded studies that were clearly irrelevant. We obtained
the full text of the remaining studies and the same three
review authors independently assessed which trials met
the predefined inclusion criteria. Disagreements were
resolved by consensus between investigators. The follow-
ing data of included studies were extracted independently
by the same three authors: first author, year of publication,
journal, study center, study population characteristics
(inclusion and exclusion criteria, age, gender, similarity of
groups at baseline, severity of SAH), sample size, interven-
tions for ETRAs (time of initiated administration, type,
dose, duration, route of administration), and treatment of
aneurysm (clip or coil). The methodological quality of
each trial was evaluated using the Jadad scale [21] and the
risk of bias assessment tool in the Cochrane Handbook for
Systematic Reviews of Interventions [22]. The criteria
included randomization, allocation concealment, blinding,
and an explanation of withdrawal or loss to follow-up.
Clinical trials with Jadad scores ≥3 were considered to
have lower bias risks. Any discrepancies were resolved by
consensus between investigators.
Statistical analysis and assessment for bias
Meta-analysis was performed to calculate the risk ratio
(RR) and 95% confidence interval (CI) via a fixed-effect
model if there is no evidence of statistical heterogeneity.
The random-effects model was employed to pool studies
when statistical heterogeneity occurred. We intended to
performed subgroup analysis according to the type and
dose of ETRAs, as well as the grade of SAH patients
(high-grade patients vs. low-grade patients) and the treat-
ment of intracranial aneurysm (clipped patients vs. coiled
patients) if possible. We assessed and quantified statisti-
cal heterogeneity for each pooled summary estimate
using Cochran’s Q statistic and the I2 statistic, respec-
tively. Substantial heterogeneity will be considered to
exist with I2 >50% and chi-squared test P<0.1. All ana-
lyses were performed using the Review Manager Soft-
ware, RevMan 5.1 (Version 5.1. Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2011).
Results
Trial selection and characteristics
The combined search strategy identified 1,673 citations
(Figure 1). After title, abstract and full-text screening, five
completed RCTs satisfied all inclusion criteria for final
Ma et al. Critical Care 2012, 16:R198
http://ccforum.com/content/16/5/R198
Page 2 of 11
analysis and included a total of 2,595 patients [16,23-26].
Four trials, involving 2,175 patients, used the endothelin-
A antagonist clazosentan compared with placebo. The
other RCT enrolled 420 patients to receive either placebo
or a mixed endothelin-A/B antagonist (TAK-044). Details
of the included studies are presented in Table 1.
Assessment of trial quality
Five eligible studies were assessed for risks of bias using
both the Cochrane Handbook for Systematic Reviews of
Interventions and the Jadad scale. All these trials were
found to have lower bias risks (Jadad score >3). Details of
our assessment of the risk of bias in the included studies
are presented in Table 2. We intended to access publica-
tion bias using a funnel plot and linear regression test, but
there were too few included studies to enable meaningful
analysis.
Effects of interventions
Mortality and unfavorable outcome
Five studies with 2,595 patients were available for analysis
of mortality and four studies with 2,547 patients were
available for analysis of unfavorable outcome (either
death or dependency). The pooled RR for mortality at the
end of scheduled follow-up was 1.03 (95% CI = 0.77 to
1.36). Heterogeneity: c2 = 0.95, degrees of freedom
(df) = 4 (P = 0.92); I2 = 0% (Figure 2). The pooled RR for
unfavorable outcome at the end of scheduled follow-
up was 1.07 (95% CI = 0.93 to 1.22). Heterogeneity:
c2 = 3.10, df = 3 (P = 0.38); I2 = 3% (Figure 3).
Angiographic vasospasm
Three studies presented the data for angiographic vasos-
pasm, involving 1,588 patients. The pooled RR for angio-
graphic vasospasm was 0.66 (95% CI = 0.57 to 0.77).
Heterogeneity: c2 = 2.66, df = 2 (P = 0.26); I2 = 25%
(Figure 4). One should note that not all patients in the
CONSCIOUS-3 study underwent angiograms (several
patients underwent computed tomography angiography
instead of digital subtraction angiography) [26], so the
data from the CONSCIOUS-3 study were not useful to
calculate the rate of vasospasm in this meta-analysis.
Delayed cerebral infarction and delayed ischemic
neurological deficit
All five studies recorded DCI, involving 2,576 patients.
The pooled RR for DCI was 0.87 (95% CI = 0.74 to 1.03).
Heterogeneity: c2 = 7.25, df = 4 (P = 0.12); I2 = 45%
(Figure 5). Four studies of 2,547 patients reported DIND.
The pooled RR for DIND was 0.77 (95% CI = 0.66 to
0.90). Heterogeneity: c2 = 1.32, df = 3 (P = 0.72); I2 = 0%
(Figure 6).
Adverse events
All five studies reported adverse events. The targeted
adverse events under observation mainly contained lung
complications, anemia, hypotension, hepatobiliary events,
cerebral hemorrhage and cardiac ischemic events.
The pooled RR for each adverse event is presented in
Figure 7. There were significant increases in lung compli-
cations (RR = 1.80, 95% CI = 1.55 to 2.09), hypotension
(RR = 2.42, 95% CI = 1.78 to 3.29) and anemia
(RR = 1.47, 95% CI = 1.19 to 1.83).
Figure 1 Flow diagram for study selection. RCT, randomized controlled trial.
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As the data for subgroup analysis between the coiling
group and the clipping group were inadequate and una-
vailable, we only performed subgroup analysis according to
the type (clazosentan vs. TAK-044; Figures 2, 3, 5, 6) and
dose (clazosentan, 5 mg/hour vs. 15 mg/hour; Figure 8) of
ETRA. The estimate for mortality in the clazosentan group
(RR = 1.04, 95% CI = 0.72 to 1.51, n = 2,175) was not
statistically different from that for the TAK-044 group
(RR = 1.00, 95% CI = 0.64 to 1.56, n = 420) with P = 0.88.
There was no difference in treatment effect on unfavorable
outcome, DCI and DIND in subgroup analysis according
to the type of ETRA. There was also no statistical differ-
ence for mortality and unfavorable outcome when ana-
lyzed according to the dose of ETRA.
Discussion
In accordance with the previous meta-analysis, the
results of our updated meta-analysis did not find evi-
dence that ETRAs could provide beneficial clinical out-
come in patients with SAH. Although ETRAs can
significantly reduce angiographic vasospasm (P
<0.00001) and DIND (P = 0.001), they did not improve
overall mortality and unfavorable outcome. There was
Table 2 Quality indicators and assessment of risk of bias in the included randomized controlled trials










Randomized controlled study Yes Yes Yes Yes Yes
Appropriate random sequence
generation
Yes Unclear Unclear Yes Yes
Allocation concealment Unclear Unclear Unclear Yes Yes
Blinding of participants and
personnel
Yes Yes Yes Yes Yes
Blinding of outcome assessment Unclear Yes Yes Yes Yes
Explanation for withdrawals and
dropouts
No Yes Yes Yes Yes
Jadad scale 4 4 4 5 5
Figure 2 Risk ratio for mortality at the end of follow-up. Comparison between endothelin-receptor antagonists (ETRAs) and placebo in
patients with aneurysmal subarachnoid hemorrhage and subgroup analysis according to type of ETRA. CI, confidence interval; df, degrees of
freedom; M-H, Mantel-Haenszel.
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also no significant reduction in DCI. In addition, pul-
monary complications, anemia and hypotension were
more common in patients receiving ETRAs compared
with placebo. The disappointing results do not support
the routine use of ETRAs in SAH patients. As hypoten-
sion and pulmonary complications are independently
associated with poor outcome after SAH [27], further
clinical trials of ETRAs in SAH patients should be more
carefully formulated and designed.
The present data revealed that there was obvious disso-
ciation between angiographic vasospasm and clinical out-
come measurements. This dissociation could result from
increased adverse events, methodological problems, insen-
sitivity of clinical outcome, sample size and other possible
processes other than angiographic vasospasm contributing
to poor outcome [28,29]. Since signs of cerebral ischemia
and vasospasm are sometimes reversible, data on vasos-
pasm or DIND in SAH clinical trials may not have been
important. In concordance with a recent consensus paper,
this meta-analysis also supports the suggestion that DCI
on CT scan is a better outcome measure in observational
studies and clinical trials than vasospasm and DIND [30].
However, because identifying DCI from all causes of CT
hypointensities may be difficult with only a plain CT scan,
Figure 3 Risk ratio for unfavorable outcome at the end of follow-up. Comparison between endothelin-receptor antagonists (ETRAs) and
placebo in patients with aneurysmal subarachnoid hemorrhage and subgroup analysis according to type of ETRA. CI, confidence interval; df,
degrees of freedom; M-H, Mantel-Haenszel.
Figure 4 Risk ratio for angiographic vasospasm. Comparison between endothelin-receptor antagonists (ETRAs) and placebo in patients with
aneurysmal subarachnoid hemorrhage. CI, confidence interval; df, degrees of freedom; M-H, Mantel-Haenszel.
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Figure 5 Risk ratio for delayed cerebral infarctions. Comparison between endothelin-receptor antagonists (ETRAs) and placebo in patients
with aneurysmal subarachnoid hemorrhage and subgroup analysis according to type of ETRA. CI, confidence interval; df, degrees of freedom; M-
H, Mantel-Haenszel.
Figure 6 Risk ratio for delayed ischemic neurological deficit. Comparison between endothelin-receptor antagonists (ETRAs) and placebo in
patients with aneurysmal subarachnoid hemorrhage and subgroup analysis according to type of ETRA. CI, confidence interval; df, degrees of
freedom; M-H, Mantel-Haenszel.
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future advanced techniques and surrogate outcomes
should also be designed and introduced [31].
In any meta-analysis, the possibility of publication bias
should be considered a potential threat to validity. In this
paper, however, we believe that the risk of publication
bias affecting the results is minimal due to our extensive
and sensitive searching. The high quality of the included
RCTs also reduced potential sources of risk of bias.
Figure 7 Risk ratio for adverse events. Comparison between endothelin-receptor antagonists (ETRAs) and placebo in patients with aneurysmal
subarachnoid hemorrhage. CI, confidence interval; df, degrees of freedom; M-H, Mantel-Haenszel.
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There is no evidence for statistical heterogeneities in
pooled analysis of each outcome. However, in this meta-
analysis, four limitations should be noted. First, angiogra-
phy was not routinely performed in all included studies -
this would decrease the correlations among vasospasm,
DCI, and clinical outcome. Second, explicit definitions
for hypotension or pulmonary complications were not
classified in the included studies. Similarly, the definition
of DIND is not identical between the CONSCIOUS stu-
dies and the TAK-044 trial. Third, four included RCTs
and our paper use angiographic vasospasm as an out-
come measure, but vasospasm of microvessels cannot be
visualized on angiography and there is no established cri-
terion for the definition of angiographic vasospasm.
Figure 8 Mortality and unfavorable outcome according to clazosentan dose. Subgroup analysis for mortality and unfavorable outcome at
the end of follow-up according to the dose of clazosentan. CI, confidence interval; df, degrees of freedom M-H, Mantel-Haenszel.
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Fourth, the treatment of intracranial aneurysm in each
included study is not unanimously identical (Table 1).
We intended to obtain unpublished data for subgroup
analysis (coiling vs. clipping), but no additional data are
available to construct the subgroup analysis. The con-
founding factor of different treatments for intracranial
aneurysm should be considered a source for risk of bias
and heterogeneities for the pooled data.
Conclusion
There is no evidence that ETRAs could benefit clinical
outcome in patients with SAH. Owing to the increased
adverse events, further clinical trials of ETRAs in SAH
patients should be more carefully formulated and
designed. The present results also suggest that DCI may
be a better outcome measure than vasospasm and DIND
in clinical trials and observational studies.
Key messages
• Pilot studies suggested that ETRAs prevent both
radiographic vasospasm and DINDs after SAH, but did
not indicate that they could improve clinical outcome.
Owing to recently published phase 3 clinical trials, the
previous meta-analysis on the use of ETRAs to treat
aneurysmal SAH has become outdated.
• An up-to-date systemic review and meta-analysis
indicates that ETRAs associated with increased adverse
events and did not benefit clinical outcome in patients
with SAH. Further clinical trials of ETRAs in SAH
patients should be more carefully formulated and
designed.
Additional material
Additional file 1: a table presenting the PRISMA guidelines.
Additional file 2: a diagram presenting the search strategy.
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